41 related articles for article (PubMed ID: 15097154)
1. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Nsanzabana C; Rosenthal PJ
Antimicrob Agents Chemother; 2011 Nov; 55(11):5073-7. PubMed ID: 21876053
[TBL] [Abstract][Full Text] [Related]
3. Role of tipranavir in treatment of patients with multidrug-resistant HIV.
Courter JD; Teevan CJ; Li MH; Girotto JE; Salazar JC
Ther Clin Risk Manag; 2010 Oct; 6():431-41. PubMed ID: 20957134
[TBL] [Abstract][Full Text] [Related]
4. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
Li F; Wang L; Guo GL; Ma X
Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
[TBL] [Abstract][Full Text] [Related]
5. Review of tipranavir in the treatment of drug-resistant HIV.
Streeck H; Rockstroh JK
Ther Clin Risk Manag; 2007 Aug; 3(4):641-51. PubMed ID: 18472987
[TBL] [Abstract][Full Text] [Related]
6. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG; Bonora S; Calcagno A; D'Avolio A; Siccardi M; Fontana S; Milia MG; Sciandra M; Garazzino S; Di Garbo A; Baietto L; Trentini L; Di Perri G
Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524
[TBL] [Abstract][Full Text] [Related]
7. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
[TBL] [Abstract][Full Text] [Related]
8. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
King JR; Acosta EP
Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
[TBL] [Abstract][Full Text] [Related]
9. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.
Mukwaya G; MacGregor T; Hoelscher D; Heming T; Legg D; Kavanaugh K; Johnson P; Sabo JP; McCallister S
Antimicrob Agents Chemother; 2005 Dec; 49(12):4903-10. PubMed ID: 16304151
[TBL] [Abstract][Full Text] [Related]
10. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
12. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
13. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.
McCallister S; Valdez H; Curry K; MacGregor T; Borin M; Freimuth W; Wang Y; Mayers DL
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):376-82. PubMed ID: 15097154
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Yeni P
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
